Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

IF 27.4 1区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY Advanced Materials Pub Date : 2025-02-12 DOI:10.1002/adma.202417348

Liane IF Moura, Alessio Malfanti, Ana I Matos, Carina Peres, Ana Armiñán, Aroa Duro‐Castaño, Inmaculada Conejos‐Sánchez, María Medel, Snežana Đorđević, Paula Carrascosa, Bárbara Carreira, Rita C Acúrcio, Helena Xavier‐Ferreira, Alberto Hernández‐Barranco, Elena Castellano, Esther Roselló, José C. Machado, Héctor Peinado, María J. Vicent, Helena F. Florindo

{"title":"Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma","authors":"Liane IF Moura, Alessio Malfanti, Ana I Matos, Carina Peres, Ana Armiñán, Aroa Duro‐Castaño, Inmaculada Conejos‐Sánchez, María Medel, Snežana Đorđević, Paula Carrascosa, Bárbara Carreira, Rita C Acúrcio, Helena Xavier‐Ferreira, Alberto Hernández‐Barranco, Elena Castellano, Esther Roselló, José C. Machado, Héctor Peinado, María J. Vicent, Helena F. Florindo","doi":"10.1002/adma.202417348","DOIUrl":null,"url":null,"abstract":"Tumor‐associated antigen‐based cancer vaccines suffer from limited clinical success compared to alternative immunotherapies in melanoma, an aggressive skin cancer with an immunosuppressive tumor microenvironment. The anti‐tumor potential of a multivalent nanoconjugate cancer vaccine platform – a cross‐linked star‐shaped polyglutamate carrier (StCl) with marked lymphotropic character conjugated with melanoma‐associated peptide antigens is evaluated through redox‐responsive linkers. The co‐delivery of melanoma‐associated peptide antigens by the nanoconjugate platform induced significant effector immune responses in a mouse melanoma model. The nanoconjugate platform synergized with a PD‐1 inhibitor to revert the immunosuppressive melanoma tumor microenvironment by improving cytotoxic T‐cell infiltration, which prompted a superior anti‐tumor effect with prolonged overall survival without acute organ toxicity. The antigen‐specific anti‐tumor immune response induced by the nanoconjugate platform is also validated in a melanoma patient‐derived xenograft mouse model. A promising, versatile StCl‐based platform is reported for generating off‐the‐shelf multivalent nanoconjugate cancer vaccines for the safe and efficient immunotherapeutic treatment of melanoma.","PeriodicalId":114,"journal":{"name":"Advanced Materials","volume":"103 1","pages":""},"PeriodicalIF":27.4000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Materials","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1002/adma.202417348","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Tumor‐associated antigen‐based cancer vaccines suffer from limited clinical success compared to alternative immunotherapies in melanoma, an aggressive skin cancer with an immunosuppressive tumor microenvironment. The anti‐tumor potential of a multivalent nanoconjugate cancer vaccine platform – a cross‐linked star‐shaped polyglutamate carrier (StCl) with marked lymphotropic character conjugated with melanoma‐associated peptide antigens is evaluated through redox‐responsive linkers. The co‐delivery of melanoma‐associated peptide antigens by the nanoconjugate platform induced significant effector immune responses in a mouse melanoma model. The nanoconjugate platform synergized with a PD‐1 inhibitor to revert the immunosuppressive melanoma tumor microenvironment by improving cytotoxic T‐cell infiltration, which prompted a superior anti‐tumor effect with prolonged overall survival without acute organ toxicity. The antigen‐specific anti‐tumor immune response induced by the nanoconjugate platform is also validated in a melanoma patient‐derived xenograft mouse model. A promising, versatile StCl‐based platform is reported for generating off‐the‐shelf multivalent nanoconjugate cancer vaccines for the safe and efficient immunotherapeutic treatment of melanoma.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Advanced Materials 工程技术-材料科学：综合

CiteScore

43.00

自引率

4.10%

发文量

2182

审稿时长

2 months

期刊介绍： Advanced Materials, one of the world's most prestigious journals and the foundation of the Advanced portfolio, is the home of choice for best-in-class materials science for more than 30 years. Following this fast-growing and interdisciplinary field, we are considering and publishing the most important discoveries on any and all materials from materials scientists, chemists, physicists, engineers as well as health and life scientists and bringing you the latest results and trends in modern materials-related research every week.